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9 Colorectal cancer is a leading cause of cancer related mortality in the Western world. In recent years,
10 combination 5-
^
ﬂuorouracil based adjuvant chemotherapy as ﬁrst line treatment of this disease has
^
led to
11 improved disease free and overall survival. However drug resistance, both innate and acquired, remains an
12 obstacle in the effective treatment of this disease. Apoptotic pathways are frequently altered in both tumor
13 progression and drug resistance; therefore proteins associated with this pathway may have potential as
14 prognostic biomarkers for this disease. Identiﬁcation of clinical biomarkers that are able to identify patients
15
^
who are more likely to respond to speciﬁc chemotherapy will lead to more personalized, effective, and less
16 toxic therapy. This review focuses on the current status of apoptosis related proteins as biomarkers for
17 colorectal cancer and discusses the possible application of systems approaches in this context.
18 © 2009 Published by Elsevier B.V.
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491.1. Current prognosis of colorectal cancer
50Colorectal cancer is the third most common form of cancer and
51the second leading cause of cancer related mortality in the Western
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52 world. The current standard of care for colorectal cancer patients is
53 primarily dictated by disease stage. When diagnosed at an early
54 localized disease stage (Dukes A), patients undergo curative surgical
55 resection. Dukes B patients, in which there is localized spread with
56 no lymph node involvement, are treated surgically with or without
57 5-
^
ﬂuorouracil (5FU) based adjuvant chemotherapy. The 5-
^
year
58 survival of Dukes B patients undergoing surgical resection alone is
59 approximately 75%, indicating that only/maximal 25% of Dukes B
60 patients may potentially beneﬁt from adjuvant chemotherapy. In the
61 advanced disease setting, in which there is lymph node involvement
62 (Dukes C) or metastasis to other organs (Dukes D), the current
63 treatment paradigm is surgical resection followed by adjuvant 5FU
^
-
64
^
based chemotherapy. As monotherapy, the anti-
^
metabolite 5FU has
65 response rates of approximately 10–
^
15%, recently however response
66 rates and disease-
^
free survival have improved due to shifts in
67 treatment paradigms to 5FU-
^
based combination therapy, namely
68 with the platinum agent oxaliplatin [1,2] or the topoisomerase I
69 inhibitor, irinotecan (CPT-
^
11) [3].
70 Currently there are no clinically-
^
used/routine biomarkers which
71 accurately predict whether colorectal cancer patients will or will not
72 respond to adjuvant chemotherapy. Therefore there is an urgent need
73 for the determination of useful prognostic markers at both the
74 pathological and biochemical/molecular level. Identiﬁcation of such
75 biomarkers is particularly important for the stratiﬁcation of Dukes B
76 patients as the beneﬁt of adjuvant chemotherapy in this group of
77 patients is not clearly deﬁned [4].
78 1.2. Biomarkers: where we stand now
79 The key prognostic indicator for colorectal cancer is tumor staging,
80 with other possible indicators for disease prognosis including
81 microsatellite instability (MSI) [5–8], anatomic location of tumor [9],
82 and DNA content [7]. In 2002, Peterson et al.
^
identiﬁed four
83 pathologically deﬁned markers to potentially be used in stratifying
84 Dukes B patients for relapse following surgical resection, and there-
85 fore would beneﬁt from adjuvant chemotherapy [10]. These patholo-
86 gical markers were deﬁned as peritoneal spread, venous spread,
87 surgical margin spread, and tumor perforation. Each were scored to
88 generate a prognostic index (PI) with patients classiﬁed as low risk
89 (PI=0 or 1) or high risk (PI≥2) for recurrence. The effectiveness of this
90 method of stratiﬁcation of Dukes B patients was recently shown to be
91 limited due to often inadequate pathological reporting [11], indicating
92 an ever pressing need for the identiﬁcation of useful biochemical
93 markers.
94 Current chemotherapy regimens for colorectal cancer consist of
95 classical cytotoxic chemotherapeutic agents, however this is poised
96 to change as discovery of disease biomarkers may represent novel
97 therapeutic targets. Categorizing patients for therapy based on the
98 presence or absence of certain markers may ultimately lead to
99 more individualized therapies which are more effective and less
100 toxic. Genes and/or proteins which may be potential response
101 biomarkers that are frequently determined in the in vitro preclinical
102 setting and are often identiﬁed as knowledge of
^
drug
^
mechanisms
103 of action and/or resistance are determined. Accordingly insight into
104 drug action and resistance, along with knowledge of disease
105 progression often
^
has served as a spring board for translational
106 studies aiming to determine their effectiveness as response
107 biomarkers. In colorectal cancer, several such biomarkers have
108 been identiﬁed for 5FU and oxaliplatin response, namely thymidy-
109 late synthase [12,13], thymidine phosphorylase [14,15], dihydropyr-
110 imidine dehydrogenase [16] and ERCC-
^
1 (excision repair cross-
111
^
complementing 1) [13].
112 More recently, advances in technology (i.e. DNA microarrays) have
113 provided additional insight into disease progression as well as into
114 mechanisms of drug action and resistance. Preclinical microarray
115 studies aimed at further understanding the mechanisms of action and
116resistance to traditional chemotherapies have identiﬁed markers
117which may represent novel drug targets or play a role in determining
118colorectal cancer prognosis [17–19]. Clinical studies of other malig-
119nancies have also identiﬁed ‘gene signatures’whichmay be important
120in diagnosis and treatment selection [20,21].
121This review will focus on the current status of prognostic markers
122for colorectal cancer, with a focus on apoptosis associated biomarkers.
1232. Apoptosis resistance and colorectal cancer
1245FU, oxaliplatin and irinotecan exert their cytotoxic effects via the
125induction of the DNA damage response, which leads to cell cycle arrest
126and/or the induction of apoptosis. Apoptosis occurs through the
127intrinsic and extrinsic pathways (Fig. 1), both of which can be induced
128by these chemotherapeutics.
129The intrinsic or mitochondrial pathway is characterized by the
130release of cytochrome c from the mitochondria leading to the
131activation of caspases, a family of cysteine proteases. This process is
132controlled by the BCL-
^
2 family of proteins. While having different
133molecular functions, all the Bcl-
^
2 family proteins share sequence
134homology in varying numbers of the alpha-
^
helical Bcl-
^
2 homology, or
135BH, domains. The anti-
^
apoptotic Bcl-
^
2 like proteins are the only family
136to contain 4 BH domains (BH1–
^
4) with the pro-
^
apoptotic Bax family of
137proteins and the BH3-
^
only proteins sharing sequence homology in the
138BH1–
^
3 and BH3 domains respectively. Apoptotic signaling triggers a
139conformational change in the pro-
^
apoptotic Bax and Bak proteins
140which allows them to insert into the outer mitochondrial membrane,
141causing the release of cytochrome c and other pro-
^
apoptotic
142molecules. Activation of Bax and Bak and subsequent mitochondrial
143membrane permeabilization is modulated by the Bcl-
^
2 family of
144proteins and the pro-
^
apoptotic BH3 only families of proteins. BH3 only
145proteins bind to and inhibit the pro-
^
survival Bcl-
^
2 like familymembers
146and may potentially also directly activate Bax and Bak. The release of
147cytochrome c from the mitochondria triggers the activation of the
148initiator caspase 9, which goes on to activate the effector caspases
149(caspases 3, 7).
150The extrinsic apoptotic pathway is triggered through the activation
151of death receptors on the cell membrane and can activate caspases
152partially independent of the mitochondria. In this pathway, activation
153of death receptors [Fas, Death Receptors 4 and 5 (DR4, DR5)] by their
154respective ligands [FasL and TRAIL (tumor necrosis factor (TNF)-
155
^
related apoptosis-
^
inducing ligand)] leads to recruitment of the
156adaptor molecule FADD (Fas associated death domain) which in turn
157results in the activation of caspase 8 which in turn activates the
158effector caspases [22]. Caspase 8 activation also leads to the cleavage
159and activation of the BH3 only protein Bid, linking the extrinsic to the
160intrinsic apoptotic pathway (Fig. 1). Both the extrinsic and intrinsic
161apoptotic pathways are tightly regulated and can also be controlled by
162the inhibitor of apoptosis (IAP) proteins (Survivin, XIAP, cIAP1 and
163cIAP2). IAP proteins inhibit the enzymatic activity of caspases and also
164trigger their proteasomal degradation. The mitochondrial release of
165the pro-
^
apoptotic SMAC/DIABLO protein during apoptosis can over-
166come this block.
167Defects in the apoptotic pathway have the potential to confer a
168survival advantage to cells, contributing to the malignant pheno-
169type. Importantly, alterations in the expression of and mutations in
170apoptosis associated proteins represent important mechanisms for
171tumors to become chemoresistant. This chemoresistance may be
172inherent leading to lack of response, or maybe acquired during the
173course of treatment leading to disease recurrence. The key role of
174the apoptotic pathway in cancer progression and response to
175therapy therefore indicates that associated proteins have potential
176as cancer prognostic biomarkers. New targeted drug therapies
177aimed at interfering with apoptotic signaling have been developed
178and have been examined in preclinical studies and tested in clinical
179trials. TRAIL agonist and activating antibodies, Bcl-
^
2 antagonists/
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180 BH3
^
mimetics, SMAC mimetics, and
^
proteasome inhibitors are
181 examples of these targeted therapies which may be effective in the
182 treatment of colorectal cancer. The identiﬁcation of patients who
183 will beneﬁt from these therapies will be facilitated by identiﬁcation
184 of these biomarkers.
1853. Upstream of the mitochondria: Bcl-
^
2 family members as
186biomarkers for CRC
187Mitochondrial mediated apoptosis associated proteins are fre-
188quently studied for use as biomarkers in cancer. In particular, as key
Fig. 1.
^
The extrinsic and intrinsic apoptotic pathways.
Table 1t1:1
Bcl-2 family apoptotic proteins in colorectal cancer: clinical ﬁndings
t1:2
t1:3 Protein Function Clinical ﬁndings References
t1:4 Bcl-2 like family Bcl-2 Pro-survival Protein overexpression associated with better disease free survival [41–43]
t1:5 Protein overexpression associated with better overall survival [42–48]
t1:6 Protein overexpression does not correlate with survival [49–51]
t1:7 Protein overexpression associated with unfavorable disease outcome [52]
t1:8 Bcl-XL Pro-survival Protein overexpression in patients developing from ulcerative colitis [55]
t1:9 Protein overexpression not associated with survival [45,54]
t1:10 Mcl-1 Pro-survival Decreased expression in tumors [60]
t1:11 Diffuse IHC staining in poorly differentiated tumors [61]
t1:12 Perinuclear staining associated with response to 5FU based chemotherapy [62]
t1:13 Bcl-W Pro-survival Overexpressed in tumors, no associations with outcome made [63]
t1:14 Bax family Bax Pro-apoptotic Bax (+) tumors associated with better survival [70–73]
t1:15 No differential protein expression between normal and tumor tissue [45]
t1:16 In MSI (+) patients, genetic mutations correlate with poor prognosis [74–79]
t1:17 Bax (+) and p53 (−) tumors exhibit greater response to 5FU based therapies [71,72]
t1:18 Bax (−) and p53 (−) tumors exhibit greater response to 5FU based therapies [170]
t1:19 Bak Pro-apoptotic Genetic mutations infrequent in colorectal cancer [80]
t1:20 BH3 only family Bad Pro-apoptotic Inactivating genetic mutations in tumors [84]
t1:21 Inactivated phosphorylated Bad increased in tumors [85,86]
t1:22 Elevated expression in tumors correlates with longer disease free and
overall survival in patients receiving 5FU based therapy
[87]
t1:23 PUMA Pro-apoptotic Higher protein expression in tumors, with no genetic mutations [86]
t1:24 No changes in gene expression in tumors [92]
t1:25 NOXA Pro-apoptotic No differential mRNA or protein expression between normal and tumor tissue [93]
t1:26 Bik/nbk Pro-apoptotic Genetic mutations infrequent in colorectal cancer [94]
t1:27 Bid Pro-apoptotic Elevated protein expression in tumors did not correlate with disease survival. [151]
t1:28 No difference in expression between tumor and matched normal tissue [45]
t1:29 Elevated expression in tumors correlates with longer disease free and overall
survival in patients receiving 5FU based therapy
[87]
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189 regulators of this pathway, the Bcl-
^
2 family members are among the
190 most frequently studied as apoptotic biomarkers in a variety of tumor
191 types, including colorectal cancer. The three subfamilies and their
192 current status as biomarkers for colorectal cancer are discussed below
193 and summarized in Table 1.
194 3.1. Bcl-
^
2 like proteins
195 The pro-
^
survival Bcl-
^
2 like subfamily members include Bcl-
^
2
196 [23,24], Bcl-
^
XL [25], Mcl-^
1 [26,27] and Bcl-
^
w [28]; all of which have
197 been examined for their use as biomarkers in a variety of human
198 cancers, including colorectal cancer. Bcl-
^
2 was ﬁrst identiﬁed as an
199 oncogene in B-
^
cell lymphoma with constitutive over-
^
expression
200 resulting from the t(
^
14:18) chromosomal translocation [29] and was
201 subsequently identiﬁed as a key inhibitor of apoptosis [23,24]. Bcl-
^
2
202 is one of the most frequently examined apoptotic protein for
203 potential clinical use as a prognostic biomarker in cancer. In addition
204 to its role in apoptosis regulation, Bcl-
^
2 has also been shown to
205 regulate autophagy, playing a protective role [30]. Aberrant expres-
206 sion of this protein has been shown in a number of solid tumors [31–
207 33]. In normal colonic mucosa, Bcl-
^
2 has a distinct expression protein
208 pattern, expressed solely in the base portion of colonic crypts where
209 there is very low levels of physiological apoptosis [34], an expression
210 pattern which is lost in the progression to colorectal cancer [35,36].
211 In addition, overexpression of Bcl-
^
2 has also been associated with
212 resistance to cytotoxic drugs such as 5FU, CPT-
^
11, and cisplatin in
213 various cancer model systems [37–40]. Since the mid-
^
1990s, there
214 have been many immunohistochemical studies carried out with the
215 aim of determining the clinical utility of Bcl-
^
2 as a prognostic
216 biomarker. Surprisingly, in studies which have shown an association
217 between Bcl-
^
2 protein expression and survival, overexpression is
218 frequently associated with either better disease free survival [41–43]
219 and/or better overall survival [42–48]. However some studies have
220 shown either no correlation between Bcl-
^
2 expression and survival
221 [49–51] or that overexpression of Bcl-
^
2 correlates with unfavorable
222 outcome in colorectal cancer patients [52].
223 Based on preclinical ﬁndings linking Bcl-
^
2 expression to chemore-
224 sistance, the correlation between overexpression of Bcl-
^
2 and
225 improved survival seems counterintuitive. A possible explanation for
226 the paradoxical relationship between Bcl-
^
2 expression and clinical
227 outcome is its probable role in colorectal cancer progression. Studies
228 have shown that aberrant Bcl-
^
2 expression facilitates tumor progres-
229 sion in the early stages of colon cancer when a patient's prognosis is
230 more favorable [35,49,53,54]. Sinicrope et al.
^
which showed that while
231 Bcl-
^
2 expression did not correlate with overall survival in Dukes B
232 patients its expression did correlate with probable favorable prog-
233 nostic features such as DNA content and low proliferative index [42].
234 Taken together all of these studies indicate that while Bcl-
^
2 may be a
235 useful biomarker for colorectal cancer prognosis, its true clinical utility
236 is yet to be fully realized.
237 As a member of the anti-
^
apoptotic Bcl-
^
2 like family, over-
238 expression of Bcl-
^
XL should give cells a survival advantage and
239 confer chemoresistance [38]. In the clinical setting, there have been
240 few studies examining the prognostic value of the Bcl-
^
XL in
241 colorectal cancer. In a small study, van der Woude
^
et al.
^
examined
242 the expression of Bcl-
^
XL in the progression from chronic ulcerative
243 colitis to malignant colorectal cancer [55]. This study found that Bcl-
244
^
XL is overexpressed in patients with cancers developing with
245 ulcerative colitis, but not in the development of malignancy from
246 normal colonic mucosa [55]. Furthermore, this study ﬁnds that the
247 expression patterns seen in this study closely resemble those seen in
248 the development of esophageal cancer from Barrett's esophagus [56],
249 indicating a possible role of inﬂammation in the development of
250 these cancers. In another study, Han et al.
^
suggest that aberrant
251 expression of Bcl-
^
XL, like Bcl-^
2, may play a role in the development
252 of colorectal cancer [54]. However unlike Bcl-
^
2, the expression of
253Bcl-
^
XL has not been found to be associated with survival in these
254patients [45,54].
255A possible reason for the lack of association between expression of
256Bcl-
^
2 and Bcl-
^
XL and survival may be due to the fact that while these
257proteins are pro-
^
survival, in vitro studies have shown that over-
258expression of Bcl-
^
2 and Bcl-
^
XL results in not only an inhibition of
259apoptosis but also G0/G1 cell cycle arrest and subsequent decreased
260cellular proliferation [57–59]. While this may aid in explaining why
261Bcl-
^
2 expression associated with favorable prognostic markers such as
262low proliferative index found by Sinicrope et al. [42] it also serves to
263further complicate the use of these proteins as prognostic markers.
264Similarly to Bcl-
^
XL, there have been only a few studies which have
265examinedwhether the pro-
^
survivalMcl-
^
1 and Bcl-
^
wproteins have any
266clinical importance as a biomarker in colorectal cancer. One early study
267which examined the immunohistochemical expression of Mcl-
^
1 in
268primary tumors and adenomatous polyps found that Mcl-
^
1 staining
269was signiﬁcantly decreased in tumors but not in benign polyps
270indicating that decreased expression of Mcl-
^
1 may be a later event in
271malignant progression and/or tumor dedifferentiation [60]. Two
272studies by Backus
^
et al. both indicate that the staining patterns, rather
273than overall expression of Mcl-
^
1 protein in tumors may be important
274[61,62]. The authors hypothesized that perinuclear staining may
275indicate the presence of Mcl-
^
1 at the mitochondria and subsequent
276inhibition of apoptosis, whereas as in tumors with diffuse staining
277inhibition of apoptosis byMcl-
^
1 is altered allowing for increased tumor
278growth. An immunohistochemical analysis of Bcl-
^
w expression in
279colon cancer showed that this protein was expressed in 92% of 75
280colonic adenomocarcinomas with little expression in patients with
281adenomas and no staining in normal tissue [63]. These studies showed
282stronger staining inDukesCpatients thanDukesB indicating a possible
283role of this protein in tumor progression, however there was lack of
284sufﬁcient follow-
^
up timewithwhich tomake anycorrelations between
285Bcl-
^
w expression and treatment response or patient survival [63].
2863.2. Bax family
287Bax and Bak are essential in mitochondrial mediated apoptosis, as
288their insertion into the mitochondrial membrane triggers the release
289of cytochrome c release into the cytosol, leading to the caspase
290activation and committing the cell to apoptosis [64–67]. Bax and Bak
291are highly redundant in function, such that knocking out one does not
292alter the cells ability to undergo apoptosis, while knocking out both
293Bax and Bak leads to prevention of apoptosis [67–69].
294Of the Bax family of proteins, Bax is themost extensively studied in
295colorectal cancer. Two studies have shown that Bax positivity
296correlated with better survival outcomes than Bax negative tumors
297in advanced metastatic colorectal cancer [70–73]. Sturm et al. showed
298that with improved outcome in patients with both wild type p53 and
299Bax-
^
positive tumors [71]. In another studyexamining the expression of
300ﬁfteen apoptosis related proteins, there was no signiﬁcant difference
301found between Bax expression in tumor tissue and normal colonic
302mucosa and no correlation between Bax expression and survival was
303found [45]. Of note, genetic studies indicate that in approximately half
304of MSI positive colorectal tumors have frameshift mutations in the bax
305gene [74–79]. Inactivating mutations such as these may contribute to
306tumor progression bydisrupting the apoptotic pathway inMSI positive
307patients and have been correlated with poor prognosis [74].
308Bak has been the focus of a genomic study looking for common
309mutations and single nucleotide polymorphisms (SNPs) in colorectal
310and gastric cancers. In a cohort of 192 patients, no somatic mutations
311were found in the bak gene and any SNPs found in the coding
312sequence were also found in normal samples, indicating that genetic
313mutations in this gene are rare [80]. Due to the importance of these
314proteins in the apoptotic pathway, it is surprising that there have been
315so few studies examining their prognostic potential and future studies
316examining this are warranted.
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317 3.3. BH3 only proteins
318 BH3 only proteins are an increasingly important pro-
^
apoptotic
319 subfamily of the Bcl-
^
2 family of proteins. BH3 only protein genes are
320 transcriptional targets of stress activated transcription factors and
321 BH3 only proteins are targets of stress-
^
induced signaling cascades.
322 The BH3 only family members include Bad, Bim, Bid, PUMA, NOXA,
323 Bmk, and NBk. Most of these BH3 only family members are
324 predominantly under transcriptional control, with the exception of
325 Bad and Bid which are constitutively expressed and require post-
326
^
translational phosphorylation and cleavage for activation respec-
327 tively. Due to its role in the extrinsic apoptosis pathway, Bid will be
328 discussed in Section 5.
329 There have been several recent studies examining the role of BH3
330 only proteins as biomarkers in colorectal cancer. Bad exists in both an
331 unphosphorylated active and a phosphorylated inactive form. In the
332 active form, Bad dimerizes with either Bcl-
^
2
^
or Bcl-
^
XL preventing their
333 sequestration of Bax and promoting apoptosis [81]. Phosphorylation
334 of Bad results in its inactivation and sequestration on the cytosol,
335 allowing for cell survival [82], this survival switch is regulated by the
336 survival kinase Akt [83]. Bad has been examined at both the genetic
337 and protein level in colorectal cancer tissue. At the genetic level, Lee et
338 al. has identiﬁed two missense inactivating mutations in the BH3
339 homology domain of bad, a region essential of for its pro-
^
apoptotic
340 function in sequestration of Bcl-
^
2 and Bcl-
^
XL [84]. Studies have also
341 shown that colon cancer tumor tissue has stronger immunohisto-
342 chemical staining for phosphorylated Bad, speciﬁcally at serine 136
343 [85] and serine 112 [86] compared to normal tissue indicating that
344 increased inactivation of Bad may contribute to the dysregulation of
345 apoptosis in colorectal cancer progression. A recent study examining
346 Bad protein expression in 5FU treated colorectal cancer patients
347 showed that pretreatment Bad protein levels were higher in tumors
348 than in adjacent normal mucosa and that higher protein expression of
349 Bad correlated with longer overall survival [87].
350 PUMA and NOXA are BH3-
^
only proteins which are unique in that
351 they are transcriptionally regulated by p53 [88–90]. p53 is frequently
352 mutated in colorectal and other cancers and therefore alterations in
353 PUMA and NOXAmutational status and/or expression have biomarker
354 potential for progression of treatment response. In fact, a recent study
355 has identiﬁed both of these proteins as potential recurrence
356 biomarkers for prostate cancer [91]; however in colorectal cancer
357 thesemolecules have not been very well studied. One recent study has
358 shown that while PUMA protein is expressed in both normal and
359 colorectal tumor tissue, expression in tumors is higher than in normal
360 mucosa, with no concurrent genetic mutations in the BH3 domain
361 [86]. Another study examining PUMA gene expression and immuno-
362 histochemical staining of colorectal tumors compared to normal tissue
363 showed higher protein expression in 29% of tumors, with no
364 signiﬁcant changes at the level of gene expression [92]. Genetic and
365 protein studies of NOXA in colorectal tumors and normal tissue
366 revealed that there were no signiﬁcant differences in expression of
367 NOXA at themRNA or protein level, and that this gene does not appear
368 to be mutated in colorectal cancer [93], indicating that NOXA may not
369 be important in colorectal cancer.
370 Mutational analysis of the bik/nbk gene in MSI+ colon cancers were
371 not able to show any mutations [94], with the authors indicating that
372 this protein likewise may have little if any role in colorectal cancer
373 progression.
374 4. Downstream of the mitochondria
375 4.1. Caspase activation in the intrinsic apoptosis pathway
376 Following release from the mitochondria, cytochrome c complexes
377 with APAF-
^
1 (apoptotic peptidase activating factor 1) to form the
378 apoptosome, which then recruits and activates pro-
^
caspase 9 [95,96].
379While cytochrome c is the key component of the apoptosome, it has
380seldom been studied as a biomarker in cancer and to the best of our
381knowledge has not been examined in colorectal cancer. One study
382examined serum cytochrome c levels in a variety of tumor types
383treated with different chemotherapeutics, showing that high serum
384cytochrome c was a negative prognostic marker in chemotherapy
385treatment. Importantly, the authors suggest that serum cytochrome c
386levels may in the future be used in combination with other tumor
387markers for stratifying high risk patients [97].
388With its role in promoting apoptosis, it would be expected that
389APAF-
^
1 be associated with better overall survival. One study indicated
390that APAF-
^
1 expression correlated with longer overall survival in early
391stage colorectal cancer [45]. Similarly another study has shown that in
392rectal cancer, less than 50% of pretreatment biopsies stained positively
393for APAF-
^
1 and that positivity signiﬁcantly correlated with complete
394response to radiotherapy [98]. A recent study has shown that loss of
395APAF-
^
1 expression at the protein level was correlated with shorter
396overall survival without making any correlations to response to
397chemotherapy [99]. These studies indicate that APAF-
^
1 is promising as
398a potential prognostic biomarker. However, it should also be taken
399into consideration that the APAF-
^
1 gene has been shown to be
400inactivated throughmethylation of its promoter inmelanoma patients
401[100]. Epigenetic silencing of APAF-
^
1 may therefore contribute to any
402loss of protein expression seen in colorectal cancer patients and
403should be examined.
4044.2. The caspase family
405The key effector
^
molecules in the apoptotic pathway are caspases,
406a family of cysteine proteases whose proforms are activated
407thorough proteolytic cleavage in both the mitochondrial and death
408receptor mediated apoptotic pathways. The caspase family consists of
409two groups, the initiator and effector caspases. Following their
410activation, the initiator caspases go on to activate the effector
411caspases. As previously stated, in mitochondrial mediated apoptosis
412formation of the apoptosome leads to the activation of the initiator
413caspase 9 which in turn activates the effector caspases 3 and 7. The
414effector caspases 3 and 7 are highly similar in function, such that in
415knock out model systems, a cell
^
susceptibility to apoptosis is not
416completely abrogated unless both are concurrently knocked out
417[101]. Due to their key role in cell death, caspases and modulators of
418their activity have potential as serve as biomarkers of response to
419chemotherapy.
420There is some evidence of alterations in the expression of caspase
421family members in colorectal cancer, at both the genetic and protein
422levels. Palmerini et al.
^
examined the protein expression of caspases 7
423and 9 in matched tumor and normal tissue by immunohistochem-
424istry [102], and showed a decrease in their protein expression.
425Caspase 7 showed the largest differential expression, with 85% of
426tumors showing marked downregulation of protein. Two genetic
427studies by Soung et al.
^
identiﬁed mutations in both the caspase 3
428[103] and caspase 7 [104] genes in a number of tumor types,
429including a small percentage of colon cancers. One recent study has
430shown elevated procaspase 3 protein in colorectal cancer tumor
431tissue compared to adjacent normal [105]. However, the clinical
432implications of these ﬁndings have not been fully studied. Leonardos
433et al. showed that the enzyme activity of caspase 3-
^
like proteases
434was signiﬁcantly elevated in colorectal carcinomas compared to
435matched normal tissue. However, this upregulation did not correlate
436with prognostic factors such as tumor stage, grade, location or
437patient age [106].
438The number of studies examining the expression of caspases in
439colorectal cancer is very limited and they have not examined any
440correlation between expression and patient survival (summarized in
441Table 2). Therefore the clinical utility of caspases as colorectal cancer
442prognostic markers needs further investigation.
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443 4.3. Inhibitors of apoptosis proteins
444 The IAP family of proteins are important regulators of caspase
445 activity and apoptosis with family including cIAP1, cIAP2 [107], XIAP
446 [108] and Survivin [109]. All of these IAP family members have been
447 shown to bemore highly expressed in tumor tissue than normal tissue
448 in a cohort of Dukes B patients [45]. Coupled with their biological role
449 in cell survival, IAP family members have potential as prognostic
450 markers and have been studied in a variety of tumor types, [reviewed
451 in [110]], including those of the gastrointestinal tract [111–113].
452 Survivin has received the greatest amount of attention in studies
453 evaluating the prognostic potential of IAP family members in color-
454 ectal cancer. Survivin has also been shown to play a role in cell division
455 as it functions as a regulator for mitosis via its role in regulating
456 microtubule dynamics, indicating that the overexpression of this
457 protein may not only inhibit apoptosis but also lead to aberrant
458 mitosis and malignancy [114,115]. Due to its roles in both cell survival
459 and in cell division, Survivin is an attractive candidate as a prognostic
460biomarker for colorectal cancer. Several studies have shown poorer
461survival rates in colorectal cancer patients overexpressing Survivin
462mRNA [116] and protein [113,117]. Focusing on Dukes B patients, an
463immunohistochemical study conducted by Sarela, et al.
^
demonstrated
464that Survivin negative patients had a 94% 5-
^
year survival rate
465following curative resection compared to 52% for Survivin positive
466patients, indicating that expression may aid in stratifying Dukes B
467patients for adjuvant chemotherapy [113]. Aside from the expression
468of Survivin at themRNA and protein levels, the subcellular localization
469of Survivin may also have prognostic potential. One study has shown
470that elevated Survivin cytoplasmic staining correlates with better
471overall survival in colorectal cancer patients [112]. Survivin has also
472been studied as a marker for cancer diagnosis, Rohayem et al.
^
detected
473survivin auto-
^
antibodies in the sera of both lung cancer and colorectal
474cancer patients [118]. Monitoring survivin mRNA levels in the blood of
475gastrointestinal cancer patients following surgical resection may play
476a role similar to carcinoembryonic antigen (CEA) in monitoring a
477patient for recurrence [111].
478Far less is known about the prognostic role of other IAP family
479members in colorectal cancer, in particular XIAP which is the most
480potent and long-
^
lived caspase inhibitor of this pathway. The study by
481Krajewska et al.
^
involving a large panel of apoptosis biomarkers
482demonstrated a correlation between elevated cIAP2 and shorter
483survival, with no correlation between survival and the expression of
484cIAP1, XIAP, and survivin [45]. These ﬁndings are similar to a study
485examining the levels of these proteins in prostate cancer [119].
486While the prognostic importance of IAP family members remains
487unclear, regulators of their activities such as SMAC and XIAP-
488
^
associated factor 1 (XAF1) may also have biomarker potential. SMAC
489is released in conjunctionwith cytochrome c, where it then goes on to
490bind to IAPs and allow for caspase activation. SMAC protein has been
491shown to be highly expressed in solid tumors of the stomach, colon,
492lung, ovaries, and prostate [120]. An immunohistochemical study
493demonstrated that SMAC is overexpressed in Dukes B colorectal
494tumors, compared to normal mucosa, but expression was not
495correlated with survival [45]. A recent study examining the gene
496expression of XAF1, a negative regulator of XIAP, in colon carcinoma,
497benign adenomas, and polyps showed that XAF-
^
1 mRNA levels are
498higher in colon carcinoma than in benign adenomas and polyps, with
499the authors suggesting that this molecule may play a role in colon
500cancer progression [121]. Clinical studies examining the expression of
501IAP family members and their modulators are summarized in Table 2.
5025. Bypassing the mitochondria (or not): outside signals, the
503extrinsic pathway of apoptosis
504Due to its role in cell death, members of the extrinsic apoptotic
505pathway hold potential as biomarkers and therapeutic targets in
506colorectal cancer. Activation of this pathway occurs through the
507binding of death receptors (Fas, DR4 and DR5) with their respective
508ligands (FasL and TRAIL) (Fig. 1). In colorectal cancer the death
509receptor Fas (CD95), a TNFR (Tumor necrosis family receptor)
510superfamily member and its ligand FasL are thought to be involved
511in disease progression. This may be in part due to the FasL
512overexpression of colon cancer cells which allows cells to avoid cell
513death by the immune response [122], although there is no consensus
514on role of FasL in this role [123–126]. Immunohistochemical staining
515of FasL is frequently elevated in tumors and that FasL positivity is
516associated with later stage of disease and poorer survival [127,128].
517However, another study has shown conﬂicting results, with greater
518FasL expression associated with better disease outcome and early
519stage [129]. The Fas pathway has also been implicated in the
520mechanisms of action of 5FU [130] and therefore its potential as a
521chemotherapy response marker has also warranted examination. In a
522study of patients of metastatic Dukes D patients, the expression of
523neither Fas nor FasL correlated with response to 5FU [131]. Serum
Table 2t2:1
Caspases and modulators of their activity in colorectal cancer: clinical ﬁndings
t2:2
t2:3 Protein Clinical ﬁndings References
t2:4 Caspase family Caspase 9 Decreased protein expression
in tumors
[102]
t2:5 Caspase 7 Decreased protein expression
in tumors
[102]
t2:6 Genetic mutations in gene
identiﬁed
[104]
t2:7 Caspase 3 Genetic mutations in gene
identiﬁed
[103]
t2:8 Elevated caspase 3 protein in
tumor tissue
[105]
t2:9 Caspase 3-like activity
elevated in tumor tissue
[106]
t2:10 Caspase 8 Inactivating genetic mutation
in a small subset of patients
with invasive colorectal
carcinoma
[143]
t2:11 Moderate increase in caspase 8
protein expression in tumors
[102]
t2:12 Modulators of
caspase activity
Survivin mRNA overexpression associated
with poor survival rates
[116]
t2:13 Increased protein expression in
tumors compared to matched
normal
[45]
t2:14 Protein overexpression
associated with poor survival
rates
[113, 116]
t2:15 Cytoplasmic staining associated
with better overall survival
[112]
t2:16 cIAP1 Increased protein expression
in tumors compared to
matched normal
[45]
t2:17 cIAP2 Increased protein expression
in tumors compared to
matched normal
[45]
t2:18 Increased protein expression
correlated with shorter
overall survival
[45]
t2:19 XIAP Increased protein expression
in tumors compared to
matched normal
[45]
t2:20 APAF-1 Protein expression correlates
with better overall survival
[45]
t2:21 IHC positive rectal cancer
patients correlates with
complete response to
radiotherapy
[98]
t2:22 Loss of protein expression
correlates with shorter
overall survival
[99]
t2:23 SMAC Overexpressed in tumor
tissue, no correlation
to survival
[45]
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524 levels of Fas have been shown to be elevated in patients with colon
525 cancer [132] indicating that serum levels may have ability to serve as a
526 prognostic marker. One study by Nadal et al. has shown that serum Fas
527 levels are further elevated following treatment with oxaliplatin.When
528 measured in conjunction with serum FasL, a greater than 1.2 ratio of
529 Fas/FasL is associated with response to oxaliplatin chemotherapy, with
530 ratios less than this associated with oxaliplatin resistance [133].
531 The binding of TRAIL to its receptors DR4 and DR5 also activates
532 the extrinsic apoptotic pathway and it has been shown that cancer
533 cells are more susceptible to apoptosis induced by TRAIL than normal
534 cells [134,135]. Therefore potential cancer therapeutics targeting this
535 pathway have been developed in order to increase the amount of
536 apoptotic cell death by direct activation of the TRAIL receptor
537 mediated cell death. These targeted therapies have potential in the
538 cancer therapy and include recombinant TRAIL and monoclonal
539 agonist antibodies directed against the TRAIL receptors [136]. There
540 have been few studies examining the role of TRAIL and its receptors
541 DR4 and DR5 as colon cancer biomarkers. In comparisons of colorectal
542 tumors and matched normal mucosa, studies have shown that
543 tumoral expression of TRAIL is frequently lower than in normal
544 mucosa [137,138]; in contrast one has shown higher tumoral TRAIL
545 levels [139]. Studies examining the levels of the TRAIL receptors DR4
546 and DR5 all show higher expression of both receptors in colonic
547 tumors compared to normal tissue [137–139]. In the study by van
548 Geelan
^
et al. overexpression of DR4, but not TRAIL or DR5 correlated
549 with worse disease free survival and shorter time to recurrence in
550 Dukes C patients [139], indicating that levels of this protein may have
551 some clinical use in deciding a patients chemotherapy regimen. In
552 addition to the DR4 and DR5, the decoy receptors DcR1, DcR2 and
553 DcR3may have clinical importance. These receptors bind to TRAIL, but
554 lack a death domain and therefore have pro-
^
survival rather than pro-
555
^
death effects [22,140,141]. In a study examining the levels of DcR3 in
556 colorectal patients and response to chemotherapy, Mild et al.
^
found
557 higher genetic copy numbers and protein overexpression of DcR3 in
558 patients with colorectal cancer, and that patients with higher gene
559 copy number had worse disease free and overall survival compared to
560 patients with normal copy number [142].
561 Following death receptor activation, caspase 8 is activated via its
562 interactions with FADD. Mutational analysis of the caspase 8 gene
563 revealed the presence of an inactivating mutation in a small subset of
564 patients with invasive colorectal carcinoma [143]. These mutations
565 were not present in colonic adenomas, indicating that thesemutations
566 may contribute to the pathogenesis of disease. In examining the
567 immunohistochemical expression of a number of caspases in color-
568 ectal cancer, Palmerini et al. showed a moderate increase in caspase 8
569 expression in tumors [102]. Activation of caspase 8 by FADD can be
570 inhibited by cFLIP, which has been shown to inhibit TRAIL induced
571 apoptosis in a number of cancer model systems [144]. cFLIP exists in
572 two forms, a long form cFLIP-
^
L and a short form cFLIP-
^
s, both of which
573 are capable of inhibiting caspase 8 activation and TRAIL induced cell
574 death [145]. cFLIP-
^
L has been shown to be more highly expressed in
575 adenomocarcinomasQ1 of the colon compared to premalignant polyps
576 and normal colonic tissue at both the mRNA and protein levels,
577 indicating that alterations in cFLIP-
^
L levels may contribute to the
578 malignant phenotype [146]. A recent study correlating cFLIP expres-
579 sion to colorectal cancer patient survival indicates that strong
580 immunohistochemical staining of cFLIP-
^
L, but not cFLIP-
^
s correlates
581 with poor prognosis [147].
582 In addition to the activation of caspases independent of the
583 mitochondria, the death receptor signaling pathway can also
584 contribute to release of cytochrome c from the mitochondria.
585 Following activation by FADD, caspase 8 goes on to cleave and activate
586 the BH3 only protein Bid [148,149]. Truncated Bid (tBid) can then
587 insert itself into the mitochondria, leading to the release of
588 cytochrome c and ampliﬁcation of the cell death signal [149,150].
589 There has been very little work done in examining the role of Bid as a
590biomarker in colorectal cancer. One immunohistochemical study of
591Dukes B patients indicated that in a comparison of tumor andmatched
592adjacent normal tissue; Bid was elevated in 57% of 60 patients but that
593this did not correlate with disease survival [151]. Further analysis by
594this same group and extension of the patient cohort (n=
^
100)
^
found no
595difference in Bid expression between tumor and matched normal
596tissue [45]. Another recent immunohistochemical study by Sinicrope
597et al. showed that in addition to elevated expression of Bid protein in
598tumors compared to normal tissue, there was also a correlation
599between high Bid expression and longer overall survival in Dukes B
600and C patients receiving 5FU based chemotherapy [87].
6016. Caspase independent death
602Cell death is not limited to the apoptotic pathway, but also occurs
603in ways which are caspase independent. Caspase independent cell
604death pathways include autophagy, AIF (apoptosis initiating factor)-
605
^
induced cell death and potentially autophagic cell death. While there
606is little known regarding the role of caspase independent cell death in
607colorectal cancer prognosis or response to treatment, these pathways
608may play a role in cell death associated with chemotherapy regimens
609and therefore may have some potential as biomarkers.
6106.1. AIF
611AIF induces cell death following release from the mitochondria,
612triggered through both caspase dependent and caspase independent
613pathways. In caspase dependent cell death, AIF is released along
614with cytochrome c following permeabilization of the mitochondrial
615membrane [152]. AIF is capable of causing caspase independent cell
616death through its role in chromatin condensation and DNA
617fragmentation [152,153]. In addition to its role in apoptosis, AIF
618which works to promote survival through its role as a NADH oxidase
619in the mitochondria and in colon cancer cell lines has been shown to
620suppress cell death [154] indicating that this protein may play a role
621in malignancy. Examination of AIF in colorectal cancer found that
622while somatic mutations in AIF are rare, the majority of colorectal
623cancer tumors expressed higher levels of AIF protein than normal
624mucosa [155]. Immunohistochemical analysis of AIF expression in
625matched tumor and normal tissue showed no difference in protein
626expression [45].
6276.2. Autophagy
628Autophagy refers to the degradation and recycling of intracellular
629proteins and cellular organelles [156,157]. This can have a protective
630effect as it is plays a role in protein turnover and response to lower
631cellular energy levels [158], and it can also result in autophagic cell
632death when the levels of damage are high enough. Importantly this
633process may also be controlled by the Bcl-
^
2 family of proteins. Beclin-
^
1
634is a regulator of autophagy and has been identiﬁed as a possible tumor
635suppressor [159]. Beclin-
^
1 is kept inactive via binding to Bcl-
^
2;
636inhibition of this interaction can release Beclin-
^
1 and trigger
637autophagy. Its mutational status and expression
^
have been examined
638in malignancies, including colorectal cancer [160,161]. These studies
639found that mutations in the beclin-
^
1 gene are rare [161], but that
640proteinwas expressed in 95% of tumors, with little or no expression in
641normal tissue [160]. Further studies examining the role of the new
642ﬁeld of autophagy are clearly warranted.
6437. Multiple marker studies
644Many of the studies reviewed here examine the biomarker
645potential of multiple proteins, but they are limited in that these
646proteins are examined individually and not in combination. Indeed,
647the use of multiple markers in combination with each other is an
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648 excellent way inwhich the speciﬁcity of a prognostic or diagnostic test
649 can be increased. There are a handful of studies which have examined
650 the prognostic signiﬁcance of marker combinations in colorectal
651 cancer progression. Generally these studies have focused on a very
652 small number of empirically chosen proteins believed to be of
653 particular importance, with the focus being on Bcl-
^
2 and/or p53
654 protein. These proteins are often examined either as a pair
655 [35,42,43,46,48,162] or in combination with the proliferation marker
656 Ki-
^
67 [36,41,51,163] and/or with other molecules involved in the
657 regulation of cellular proliferation such as c-
^
Myc [36,52], cyclin D1
658 [163], p21 and p27 [164].
659 Several studies have explored the role of p53 status in conjunction
660 with apoptosis regulating proteins. The tumor suppressor protein p53
661 has a variety of molecular functions, including the induction of
662 apoptosis in response to cellular stress [165] via transcriptional
663 activation of a number of pro-
^
apoptotic target genes including the
664 BH3 only proteins PUMA [166] and NOXA, but also Bax, Bid, APAF-
^
1,
665 and caspases 9, 3, and 8 [167]. p53 mutations are a hallmark in
666 colorectal cancer progression, leading to stabilization of protein and
667 elevated immunohistochemical staining. The ability of p53 to serve as
668 a prognostic biomarker has been extensively studied in CRC, with
669 most studies focusing on increased immunohistochemical staining
670 [reviewed in [168]]. Studies have suggested that p53 protein
671 stabilization and mutations are associated with poor clinical prog-
672 nosis [36,168,169]. In a study examining whether the expression of
673 p53 AND Bcl-
^
2 in rectal cancer predicts for survival following surgical
674 resection, Schwander et al.
^
found that certain combinations of the
675 two proteins were effective in separating patients with poor and
676 favorable outcomes. Namely, patients which were p53 positive and
677 Bcl-
^
2 negative had a signiﬁcantly poorer prognosis than patients
678 which were p53 negative and Bcl-
^
2 positive [162]. Buglioni
^
et al.
679 found similar results in a cohort of colorectal cancer patients which
680 focused on patients which were Dukes stage A or B [43], indicating
681 that this combination may be of importance in the stratiﬁcation of
682 early stages colorectal cancer for adjuvant chemotherapy. Aside from
683 p53 and Bcl-
^
2 combinations, other combinations of markers have
684 been identiﬁed as colorectal cancer prognostic markers. Tornillo et al.
685
^
found that alone, the expression of p53, Bcl-
^
2, p21 and p27 on a
686 tissue microarray had prognostic signiﬁcance. However combinations
687 of these markers, namely p21/p27/p53 and p21/p27/Bcl-
^
2 were
688 predictive of survival [164].
689 One recent study has shown that while there was no correlation
690 between Bax expression and Bcl-
^
2 expression and survival, there was
691 a correlation between p53 negative and high Bax expression had
692 better survival rates than tumors which were p53 positive and had
693 high Bax expression [72] in patients receiving 5FU based chemother-
694 apy. Likewise, Sturm et al. have shown that Bax expression was
695 indicative of longer survival in patients with advanced metastatic
696 disease, and this effect was enhanced in patients whose tumors were
697 Bax positive and p53 wild type [71]. However another immunohis-
698 tochemical study aimed at correlating the expression of these proteins
699 to response to therapy showed that tumors which were p53 and Bax
700 negative had greater response rates to 5FU based therapy [170]. These
701 contradictory studies indicate that the relationship between p53 and
702 Bax needs to be more closely examined. Another study has shown that
703 tumors expressing high levels of both the BH3 only proteins Bid and
704 Bad had longer disease free and overall survival in a cohort of Dukes B
705 and C colon cancer patients undergoing 5FU based chemotherapy,
706 indicating that these markers may aid in deciding treatment regimens
707 for patients [87].
708 Recently, Krajewska
^
et al. carried out a large tissue microarray
709 study examining the expression of a large 15 apoptosis related
710 proteins in Dukes B colorectal cancer patients [45]. Protein
711 expression was determined in matched tumor and normal tissue
712 and any correlations with clinical outcome were determined. As
713 individual markers, better survival outcome was associated with low
714tumoral levels of expression of cIAP2 and the caspase 9 antagonist
715TUCAN and high tumoral levels of APAF1, and Bcl-
^
2. Analysis to
716determine the correlations between the expression of multiple
717proteins and survival indicated that certain pairwise combinations of
718proteins whose expression correlated with outcome were very
719highly predictive of patient outcome in Dukes B patients. Speciﬁcally,
720tumors expressing the combinations of low cIAP2/low TUCAN, low
721cIAP2/high APAF1, and low TUCAN/high Bcl-
^
2 were predictive of
722better outcome, with 97–
^
100% of patients with these phenotypes
723being alive at 5 year
^
s. Patients expressing combinations of proteins
724which correlated negatively with outcome; low tumoral APAF1/high
725TUCAN or high cIAP2/
^
low Bcl-
^
2, were more likely to die from
726disease. This study in particular shows the importance of examining
727the expression of multiple markers for increasing speciﬁcity for
728better or worse prognosis.
7298. Future directions: towards a systems analysis?
730The majority of clinical studies discussed in this review examine
731the qualitative expression of a small number of apoptosis related
732proteins and any correlation to clinical outcome. These studies have
733often shown differential protein expression between tumor and
734normal tissue, but as discussed above correlating these differences
735with clinical outcome has frequently produced inconsistent results.
736While informative, these multiple marker studies fail to take into
737account the complex nature of biological processes, and therefore a
738systems biology approach incorporating these interactionsmay have a
739better ability to predict responses. Apoptosis is a complex process in
740which the balance of pro-
^
and anti-
^
apoptotic proteins is tightly
741regulated in determining the fate of the cell; a balance which is
742believed to be dysregulated in cancer. For instance, this review
743highlights that in colorectal cancer some pro-
^
apoptotic proteins (Bid,
744PUMA) are overexpressed in colorectal tumors compared to normal
745tissue. Letai has proposed that such tumors may be ‘primed’ for death
746[171], that is
^
pro-
^
apoptotic proteins may be being inhibited through
747interactions with anti-
^
apoptotic proteins resulting in cell survival and
748therapy resistance. Therefore it is very likely that differences in a
749number of apoptosis proteins and their relationship to one another
750will have clinical use as prognostic markers for cancers. In addition,
751elucidation of the relationships between the various pro-
^
and anti-
752
^
apoptotic proteins is important in that these interactions represent
753novel therapeutic targets.
754We have recently developed a systems biology based, mathema-
755tical model, APOPTO-
^
CELL, [172,173] which allows to predict the
756susceptibility of cells to undergo caspase activation based on the input
757of quantitatively determined protein levels of apoptosis related family
758members (in particular Caspase 3, Caspase 9, APAF-
^
1, SMAC and XIAP).
759This model is advantageous in that it has incorporated a biological
760interaction network based on protein interaction data and hence
761represents a novel approach to identifying and utilizing apoptosis
762related proteins by looking at a system rather than a random
763combination of proteins. It enables the identiﬁcation of proteins
764which are critical in the determination of a systems fate, or more
765precisely when a protein or combination of proteins becomes
766important. For example, in a system in which the anti-
^
apoptotic
767protein XIAP is highly expressed, SMAC has little effect on cell fate.
768SMAC only becomes important when both XIAP and SMAC protein
769levels are high [173]. The identiﬁcation of proteins which are only
770important in certain scenarios may have clinical signiﬁcance in the
771development of targeted therapeutics such as SMAC mimetics. While
772the APOPTO-
^
CELL model was established in cervical cancer cells, there
773is the potential for this tool to be translated into the clinical setting
774such that it would be able to assess the probability a patient will
775respond to chemotherapy. On the basis of quantitative protein analysis,
776concentrations of apoptotic proteins (Caspase 3, Caspase 9, APAF-
^
1,
777SMAC and XIAP) would be determined followed by input into the
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778 APOPTO-
^
CELLmodel, with the prediction of caspase substrate cleavage
779 indicating whether the system is likely to undergo apoptosis. That is
780 increases in substrate cleavage indicate that apoptosis can be executed,
781 while no increases in substrate cleavage indicate that apoptosis could
782 be inhibited or severely impaired in the tumor sample and therefore
783 may serve as a surrogate marker for response. Fig. 2 represents how
784 this model may be used in predicting patient outcome.
785 Modeling of apoptosis of both the extrinsic apoptotic pathway and
786 of mitochondrial mediated apoptosis at the level of Bcl-
^
2 family
787 proteins
^
has also been and continues to be developed. Recently, a
788 model aimed at predicting for effector caspase cleavage following
789 activation of the extrinsic pathway by TRAIL has been developed [174].
790 Computational modeling of the intrinsic pathway upstream of the
791 mitochondria is difﬁcult and thesemodels are limited in that there are
792 too many unknowns or ‘black boxes’ involved in this pathway. In
793 particular, themechanisms bywhich Bax and Bak are activated are not
794 fully understood. However, initial modeling of Bcl-
^
2 family member
795 interactions is clearly a feasible approachwhichwill need to be further
796 developed and clinically applied in the future. This model can then be
797 improved upon as the black boxes of this portion of the pathway are
798 ﬁlled in.
7999. Limitations and conclusion
800The potential of apoptosis associated biomarkers for the prognosis
801in colorectal cancer
^
is vast, but not without limitation. Drug resistance
802and tumor growth are also inﬂuenced by defects in apoptosis, but
803other confounding variable such as angiogenesis, increased drug
804metabolism and drug detoxiﬁcation also contribute to resistance
805[175]. Cells also undergo alternative mechanisms of cell death such as
806necrosis, mitotic catastrophe and autophagy. While necrosis and
807autophagy can be controlled by Bcl-
^
2 family members these cell death
808pathways also occur independent of apoptosis related proteins,
809therefore the usefulness of apoptotic proteins as prognostic biomar-
810kers may be limited further.
811The recent identiﬁcation of colorectal cancer ‘stem cells’ is an
812important discovery in the colorectal cancer research [176–178].
813Cancer stem cells only represent a small portion of the tumor andmay
814be inherently resistant to current chemotherapy, thereby presenting a
815deﬁnite dilemma in how to effectively treat this disease [179,180].
816While defects in apoptosis may play a role in a patient's chemotherapy
817response, a differential dysregulation of apoptosis signaling in color-
818ectal cancer stem cells compared to non-
^
stem cells within the tumor
Fig. 2. Flow chart representing how the APOPTO-CELL systems biology model may aid in assessing patient prognosis.
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819 may limit the use of apoptotic biomarkers for use in disease prognosis
820 and response to treatment.
821 Stem cells therefore represent an important target in effectively
822 treating colon and other types of malignancies, and a deﬁnitive colon
823 cancer stem cell marker needs to be identiﬁed to truly isolate and
824 characterize this population of cells with respect to apoptosis
825 sensitivity. Previous studies have used different markers to isolate
826 and identify potential colon cancer ‘stem cells’, including CD133
827 [176,177] and CD44/EpCAM [178], which were chosen based on
828 studies in other malignancies. A recent study has questioned the use
829 of CD133 as a marker for the identiﬁcation of colorectal cancer stem
830 cells [181] and there may be other more speciﬁc markers that warrant
831 examination in isolating this cell population [182]. Clearly, the
832 importance of the apoptotic pathway in colorectal cancer stem cells
833 in patient response warrants further investigation.
834 In conclusion, determination of the tumors ability to undergo
835 apoptosis holds immense potential as a new prognostic marker for
836 colorectal cancer and to identify patients who will respond to
837 chemotherapy. Ultimately this could lead to more personalized and
838 effective cancer care.
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